Pancreatic cancer is the fourth leading cause of cancer related death. The difficulty in
detecting pancreatic cancer at an early stage, aggressiveness and the lack of effective …

The prognosis of patients with pancreatic cancer is extremely poor, and current systemic
therapies provide marginal survival benefits for treated patients. The era of targeted …

Pancreatic cancer is aggressive, chemoresistant, and characterized by complex and poorly
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …

Epidermal growth factor receptor (EGFR) plays an important role in tumor development and
maintenance. It is a cell surface molecule that mediates signal transduction from the cell …

Pancreatic carcinoma is an unusually lethal disease and to date treatment with standard
chemotherapy has yielded disappointing results. The epidermal growth factor receptor …

BACKGROUND: Pancreatic cancer remains a deadly disease, and the vast majority of
pancreatic cancer patients are not candidates for treatment with curative intent. Erlotinib, an …

Pancreatic adenocarcinoma is a common malignancy that remains refractory to available
therapies. Gemcitabine has long been the standard, first-line agent in advanced disease …

The epidermal growth factor receptor (EGFR) is considered an important therapeutic target
in pancreatic cancer, but it is currently impossible to identify those patients who are most …

Pancreatic cancer is a devastating malignancy, characterized by low responsiveness to
conventional chemotherapies. Gefitinib, an epidermal growth factor receptor-tyrosine kinase …

Pancreatic Ductal Adenocarcinoma (PDAC) is among the most lethal solid tumors with grim
prognosis. This dismal outcome can partially be explained by the resistance to currently …